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TO THE EDITOR
Syringocystadenoma papilliferum (SCAP)
is a benign cutaneous hamartomatous
tumor (Mammino and Vidmar, 1991) that
rarely undergoes transformation to mali-
gnant syringocystadenocarcinoma pap-
illiferum (SCACP) (Satter et al., 2014).
SCAPs are thought to be sweat gland
tumors, with evidence suggesting that
they may arise from a multipotent
progenitor (Yamamoto et al., 2002).
Notably, SCAPs rarely spontaneously
arise within nevus sebaceus (NS; OMIM
162900) lesions, caused by somatic
mutations inHRAS and KRAS. Additional
mutations that are necessary for SCAP
development in NS have yet to be
determined (Groesser et al., 2012).
Following a report that NS lesions result
from PTCH deletion, PTCH deletion was
also reported in some SCAP lesions (Boni
et al., 2001), although subsequent studies
found that NS results nearly exclusively
from somatic RAS mutation (Groesser
et al., 2012).
SCAP can develop spontaneously as
a solitary lesion, or it can appear in a
linear pattern at birth following Blas-
chko’s lines. Such linear patterns are
rare, and they have not been reported to
progress to malignancy. It is unclear
whether this is owing to the small
number of lesions observed or to
distinct molecular pathogenesis. Pre-
dicting that a somatic mutation would
cause linear SCAP, we interrogated
pathogenesis via paired whole-exome
sequencing (WES) of affected tissue and
blood in one case.
This study was approved by the Yale
Human Investigation Committee, and it
complies with the Declaration of Hel-
sinki guidelines. Subjects provided writ-
ten informed consent, except in the
case of archival tissue samples, which
were provided anonymized.
Our index case is a 12-year-old,
otherwise healthy, girl with no other
medical problems and no family history
of any unusual nevi. At birth, an
erythematous Blaschko-linear plaque
composed of individual papules was
noted. The lesion remained stable
throughout childhood (Figure 1a). His-
topathology revealed a cystic epithelial
invagination containing papillae lined
by columnar epithelium (Figure 1b and
c) and underlying dermis with abundant
plasma cells.
WES was performed with mean cover-
age depth of 78× in blood and 104× in
tissue (Supplementary Table 1 online).
Comparison of single-nucleotide variants
(SNVs) and small insertions and deletions
between tissue and blood revealed a
single damaging somatic SNV: BRAF c.
T1799A, p.V600E (Figure 2); 22% of
reads were mutant in tissue (39/174), and
blood had no mutant reads (0/192).
Sanger sequencing conﬁrmed this ﬁnd-
ing. Somatic loss-of-heterozygosity
(LOH) and copy-number variations were
not identiﬁed (Supplementary Figure 2
online). The ﬁnding of a single somatic
mutation without LOH provides evi-
dence that BRAF V600E mutation is
sufﬁcient to cause SCAP. In analysis of
ten solitary, sporadic SCAPs from unre-
lated subjects, we found BRAF V600E
somatic mutations in four, using DNA
from laser-capture microdissected nor-
mal epidermis as a control. To exclude
other potential pathogenic BRAF muta-
tions, we also screened exons 6, 8, 11,
12, 13, and 16, in which mutations have
been previously found in cancer and
cardiofaciocutaneous syndrome (Davies
et al., 2002; Niihori et al., 2006),
ﬁnding none.
SCAP develops in ~ 5% of NS lesions
(Groesser et al., 2012). To determine
whether such NS-associated SCAP
lesions are also driven by BRAF muta-
tion, we isolated DNA from four
SCAPs that arose within HRAS G13R
mutation–positive NS lesions. Sequen-
cing revealed no BRAF mutations
in these lesions, which were histo-
logically indistinguishable from BRAF
V600E–positive lesions (Supplementary
Table 2 online).
Recently, using a mutation-targeted
assay to interrogate genes in the
mitogen-activated protein kinase and
phosphatidylinositol-3′-OH kinase sig-
naling pathways, Shen et al. (2015)
found BRAF V600E in 12/23 screened
sporadic SCAP and activating HRAS
and KRAS mutations in 7/23 sporadic
SCAPs. Consistent with our ﬁndings,
BRAF mutations were not found in
SCAPs arising within NS. Notably, 5/6
RAS-positive lesions in the Shen study
arose on the head or neck. We also
identiﬁed a single archival sporadic
SCAP sample, which arose on the scalp
of a 16-year old, in which we found a
HRAS G13R mutation. There was insuf-
ﬁcient tissue to determine whether this
lesion arose within an NS owing to RAS
mutation. There is precedent for focal
neoplasia within RAS mutant tissue
arising via copy-number ampliﬁcation
of HRAS alleles as in spitz nevi arising
within nevus spilus (Sarin et al., 2013)
and papillomas in HRAS G12V mice
(Chen et al., 2009). This is one possible
explanation for distinct phenotypes of
NS and SCAP despite bearing identical
somatic RAS mutations.
BRAF is a serine kinase, which has a
crucial role in the RAS–RAF–MEK–ERK
signaling pathway, and mutations
including V600E have been found in
about 50% of melanomas, and in colon,
lung, and ovarian cancers (Davies et al.,
2002). Oncogenic BRAF mutations
discovered to date are restricted to
exons 11 and 15 (Davies et al., 2002),
which encode the P-loop and the
activation domains (Wan et al., 2004)
that typically interact to inactivate theAccepted article preview online 7 May 2015; published online 28 May 2015
Abbreviations: CFC, cardiofascialcutaneous syndrome; KEN, keratinocytic epidermal nevus; LOH, loss of
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enzyme. The constitutively active BRAF
V600E mutation lies within the activation
loop, disrupting this interaction (Wan
et al., 2004). Constitutional expression
of BRAF V600E causes early embryonic
lethality in mice (Dhomen et al., 2010),
and keratin-14-driven expression leads to
perinatal lethality with craniofacial
defects (Krishnaswami et al., 2014),
epidermal thickening, and loss of kera-
tinocyte differentiation markers.
RAS–RAF–MEK–ERK dysfunction has
also been observed in RASopathies with
skin and other organ abnormalities.
Weakly activating BRAF mutations cause
cardiofaciocutaneous syndrome (CFC;
OMIM 115150), featuring craniofacial
abnormalities, intellectual disability, and
cardiomyopathy (Niihori et al., 2006).
CFC can demonstrate hyperkeratotic skin
lesions on extensor surfaces of the
limbs and on the scalp and nipples, or
generalized ichthyotic scale (Niihori
et al., 2006). The marked epithelial
hyperplasia of SCAP may be owing to
stronger BRAF activation by the V600E
mutation than by more weakly activating
mutations in CFC, although further
experimental investigation is warranted.
Despite SCAP’s limited malignant
potential, it may be clinically important
to consider the possibility of transforma-
tion to carcinoma and risk of internal
malignancy in patients presenting with
large mosaic SCAP lesions at birth.
Mosaic disorders have been shown to
extend beyond the epidermis to affect
other tissues including melanocytes,
bone, and neural tissue (Lim et al., 2013).
As BRAF mutations are found in
cancer, therapeutics targeting mutant
BRAF have been developed. Vemurafe-
nib, originally developed to treat mela-
noma, targets cells with a V600E
mutation (Bollag et al., 2010). This or
similar therapeutics may provide beneﬁt
for patients with BRAF V600E–positive
SCAP lesions that are intractable to
resection, as well as for patients
with SCACP.
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Figure 1. Clinical and histological features of linear syringocystadenoma papilliferum. (a) Linear pink
hyperkeratotic papules in a 12-year-old girl have been present since birth. (b) Histopathology
demonstrates a cystic epithelial lesion containing papillary projections lined by columnar epithelium and
stromal plasma cell inﬁltration. Scale bar=500 μm.
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Figure 2. Whole-exome sequencing demonstrates BRAF V600E somatic mutation in syringocystadenoma
papilliferum (SCAPs). (a) Whole-exome sequencing was performed using paired samples, and single-nucleotide
variations (SNVs) and insertions or deletions (indels) were ﬁltered to identify protein damaging variants that are
not found in control exomes. Remaining SNVs were then ranked by ﬁsher score for tissue speciﬁcity. Only BRAF
V600E surpassed genome-wide signiﬁcance for tissue speciﬁcity (2.4×10−6), and it was conﬁrmed by Sanger
sequencing. No other mutations demonstrated a P-value o1×10−4. There were 39 nonreference reads and
147 reference reads in tissue at this site, demonstrating the presence of wild-type admixture. No nonreference
reads were found in blood. Sanger sequencing conﬁrmed that SYR101 has a tissue-speciﬁc BRAF V600E
mutation. (b) Four out of 10 sporadic SCAPs demonstrated V600E mutations identiﬁed via Sanger sequencing.
No other damaging mutations were found in exons 6, 8, 11, 12, 13, 15, or 16 in any of the samples. None of the
four SCAPs arising from within an NS that were screened demonstrated a V600E mutation.
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TO THE EDITOR
Psoriasis is a complex genetic disease,
meaning that a combination of genetic
and environmental risk factors leads to
disease manifestation. The most common
cutaneous manifestation is psoriasis vul-
garis (PV), which is strongly associated
with an HLA-C risk allele located at
psoriasis susceptibility locus 1 (PSORS1).
This locus has a greater impact on PV,
while there are many other genetic risk
factors, contributing far less. Only in some
families and single patients suffering from
PV, as well as in patients with a severe
pustular variant of psoriasis, named gen-
eralized pustular psoriasis (GPP), few
other major genetic risk factors responsi-
ble for those disease manifestations
were identiﬁed. These include missense
variants in CARD14 and loss-of-function
mutations in IL36RN described to be res-
ponsible for PV and GPP or GPP, respec-
tively (Marrakchi et al., 2011; Onoufriadis
et al., 2011; Jordan et al., 2012a, 2012b).
Palmoplantar pustular psoriasis, also
termed palmoplantar pustulosis (PPP), is
characterized by sterile pustules on
the palms and soles. It is more frequent
in women and has stronger associ-
ation with tobacco smoking than PV
or psoriatic arthritis (PsA) (O'Doherty
and MacIntyre, 1985). Although no
randomized controlled studies with bio-
logics licensed for PV have been pub-
lished, conventional therapy is similar to
PV, although there are differences in
therapeutic outcome (Marsland et al.,
2006; De Mozzi et al., 2012). Little is
known about genetic risk factors of PPP;
however, an association of PPP with
missense mutations in IL36RN has been
described recently (Setta-Kaffetzi et al.,
2013). There is an ongoing discussion on
whether PPP is a pustular variant of psori-
asis or a distinct disease entity (Ammoury
et al., 2008; Brunasso et al., 2013).
To characterize PPP genetically, we
recruited a cohort of 251 PPP patients
and screened them for the major genetic
risk factor for PV at PSORS1, as well as
for the two genes IL36RN and CARD14,
as described previously (Huffmeier et al.,
2009; Korber et al., 2013). Approval
for the studies was obtained through
the ethics committees of the respon-
sible universities. Individuals gave their
written informed consent. European
Americans from publicly available
databases, from a previous publication
(Jordan et al., 2012a), and control indivi-
duals from a German cohort (Huffmeier
et al., 2009) served as control groups (for
slight variations in control individuals,
please see Supplementary Information
online). The majority of the 251 PPP
patients was female (78.1%), and 88.4%
of recruited patients had a history of
smoking, with 75% smoking at the
time of their ﬁrst psoriatic manifestation
(Table 1, Supplementary InformationAccepted article preview online 19 May 2015; published online 18 June 2015
Abbreviations: GPP, generalized pustular psoriasis; PPP, palmoplantar pustular psoriasis; PsA, psoriatic
arthritis; PSORS1, psoriasis susceptibility locus 1; PV, psoriasis vulgaris
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